Surrozen, Inc. · NASDAQ:SRZN
Surrozen — Investor Presentation (August 2021)
36 slides from Surrozen's investor presentation, Aug 12, 2021
Slide 1: The Wnt Company – Targeted Regeneration
Exhibit 99.2 The Wnt Company – Targeted Regeneration © 2021 Surrozen, Inc.
Slide 2: Legal Disclaimers
Legal Disclaimers Forward–looking statements. Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or Surrozen, Inc.’s future financial or operating performance. For example, statements concerning the follo
Slide 3: Highlights - Compelling Breakthroughs in Harnessing Wnt Signaling
Highlights - Compelling Breakthroughs in Harnessing Wnt Signaling Global leaders in developing antibodies targeting the Wnt pathway • World renowned scientific advisors, founders • Experienced management team to execute strategy Proprietary Wnt therapeutics platform designed to selectively stimulate
Slide 4: Our Novel Approach Overcomes Previous Challenges
Our Novel Approach Overcomes Previous Challenges Paving the Way to Targeted Antibody Regeneration Integrated, Repeatable Validation of Our Prominent Role in Wnt Therapeutics Platform Wnt Biology Breakthroughs Potential first synthetic soluble Wnt mimetics Surrogate Wnt agonists that phenocopy canoni
Slide 5: Proprietary Technologies Enable Potent, Selective Wnt Signaling
Proprietary Technologies Enable Potent, Selective Wnt Signaling SWAPs & SWEETS SWAP Technology SWEETS Technology Mutated RSPO2 anti-Lrp VHH anti-Fzd IgG Cell Specific Receptor Effector-less hIgG1 Effector-less hIgG1 Antibody Based Bi-Specific Antibody-based fusion protein Mimics natural Wnt in activ
Slide 6: Deep Wnt Signaling Expertise Supports Productive R&D Pipeline
Deep Wnt Signaling Expertise Supports Productive R&D Pipeline IND Enabling Studies Ongoing for SZN-1326 and SZN-043; Planned Phase 1 Clinical Trials 2022 Lead LEAD NEXT INDICATION/S RESEARCH PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY PROGRAMS MILESTONE Programs Moderate to First in Human SZN-132
Slide 7: SZN-1326 & SZN-043 Represent Significant Market Opportunities
SZN-1326 & SZN-043 Represent Significant Market Opportunities • 2nd line biologics in UC represent a $4B market in US • Estimated 100,000 U.S. hospitalizations due to severe AH • Moderate to severe Crohn’s 2nd line market of > $7B in the US • ~50% of patients covered by commercial insurance • Opp
Slide 8: SZN-1326 Moderate to Severe IBD
anti-Lrp6 VHH anti-Fzd IgG (Fzd5) SZN-1326 Moderate to Severe IBD effector-less hIgG1 8anti-Lrp6 VHH anti-Fzd IgG (Fzd5) SZN-1326 Moderate to Severe IBD effector-less hIgG1 8
Slide 9: SZN-1326 – Intestine Targeted Epithelial Restoration Mechanism
SZN-1326 – Intestine Targeted Epithelial Restoration Mechanism Suggests Potential New Treatment Paradigm in Inflammatory Bowel Disease Microbes SZN-1326 MOA Migration Damage to epithelial cell barrier Microbial invasion DC Activated T cells Cytokines/Chemokines T cells Goblet cells Tuft cells Endocr
Slide 10: SZN-1326 – Potential to Transform Treatment Paradigm in IBD
SZN-1326 – Potential to Transform Treatment Paradigm in IBD Normal (No DSS Damage) High Unmet Need Need for rapid induction: SOC takes months to induce remission Better efficacy, especially mucosal healing: SOC achieve remission in <50% and low rates of mucosal healing (< 20%) Need for additional MO
Slide 11: Initial Clinical Development Focus on Ulcerative Colitis
Initial Clinical Development Focus on Ulcerative Colitis Potential to Expand Into Additional IBD Indications • Phase 1a in healthy volunteers dosed for up to 12 weeks IV and SQ either weekly or biweekly • Phase 1b placebo controlled in UC patients provides potential to generate clinical proof of con
Slide 12: SZN-043 Severe Liver Disease
Mutated RSPO2 Anti-ASGR1 IgG SZN-043 Severe Liver Disease Effector-less hIgG1 12Mutated RSPO2 Anti-ASGR1 IgG SZN-043 Severe Liver Disease Effector-less hIgG1 12
Slide 13: Potential for First Approved Treatment for Severe Alcoholic Hepatitis
Potential for First Approved Treatment for Severe Alcoholic Hepatitis Liver Specific Wnt Activation and Regeneration SZN-043 MOA • Selective Wnt activation Proof of Concept • Specific hepatocyte proliferation Established • Functional improvement • 2022 - First in human • 2023 – Phase 1b in severe AH
Slide 14: SZN-043 – Potential to Significantly Improve Patient Outcomes in Severe Alcoholic Hepatitis
SZN-043 – Potential to Significantly Improve Patient Outcomes in Severe Alcoholic Hepatitis AST:ALT ratio AST/ALT Ratio 20 D0 D3 D7 High Unmet Need 15 No approved drugs: SOC: steroids 10 **** 5 High mortality: 90-day mortality of 30% 0 Liver transplant denied: Limited availability, costly, denied du
Slide 15: Clinical Development Plan Provides Fast Path to POC and Approval
Clinical Development Plan Provides Fast Path to POC and Approval • Phase 1a: Potential to demonstrate clinical activity – methacetin breath test marker for hepatocyte proliferation • Phase 1b: Endpoints Lille and MELD scores highly correlated with survival; potentially lead to Fast Track Designation
Slide 16: Beyond Intestine and Liver…
Beyond Intestine and Liver… 16Beyond Intestine and Liver… 16
Slide 17: Preclinical Data Supports Advancement of Ocular Programs
Preclinical Data Supports Advancement of Ocular Programs Broad Set of Opportunities in Ocular Diseases Wet Fuchs’ Dry Sjögren’s AMD Dystrophy AMD Dry Eye • Wnt involved in corneal • Wnt involved in retinal • Wnt involved in acinar • Fzd4 maintains & pigment epithelial (RPE) cell proliferation restor
Slide 18: Near Term Outlook and Potential Milestones
Near Term Outlook and Potential Milestones Multiple Clinical Milestones with Potential for Early Proof of Concept 2021 2022 2023 Complete IND-enabling Phase 1a in Phase 1b in Ulcerative SZN-1326 Toxicology Studies Healthy Volunteers Colitis Patients INTESTINE SZN-043 LIVER 2021 2022 2023 Complete IN
Slide 19: The Wnt Company - Targeted Regeneration
The Wnt Company - Targeted Regeneration © 2021 Surrozen, Inc.
Slide 20: Appendix
Appendix © 2021 Surrozen, Inc.Appendix © 2021 Surrozen, Inc.
Slide 21: SZN-1326 Preclinical Data
anti-Lrp6 VHH anti-Fzd IgG (Fzd5) SZN-1326 Preclinical Data effector-less hIgG1 21anti-Lrp6 VHH anti-Fzd IgG (Fzd5) SZN-1326 Preclinical Data effector-less hIgG1 21
Slide 22: SZN-1326 – Restores Wnt Signaling in Damaged Intestine
SZN-1326 – Restores Wnt Signaling in Damaged Intestine Restores Wnt Signaling in Damaged Intestinal Selective Binding Profile Epithelium Selective Wnt Axin2 activation Normal Wnt No DSS Signaling Epithelial repair DSS Impaired Wnt anti-GFP Signaling Inflammation reduction DSS + Restored Wnt Function
Slide 23: SZN-1326 – Repairs Damaged Colon Epithelium
SZN-1326 – Repairs Damaged Colon Epithelium Normal (No DSS Damage) Selective Wnt Effects of SZN-1326 Administration activation • Repairs damaged colon epithelium in acute and chronic Epithelial Damaged (DSS Damage) colon injury models repair • Restores key cell lineages including colonocytes, goblet
Slide 24: SZN-1326 – Reduces Inflammatory Cytokines
SZN-1326 – Reduces Inflammatory Cytokines Colon TNF-a (pg/mg) Colon IL-6 (pg/mg) Colon IL-8 (pg/mg) Colon TNF-�� (pg/mg) Colon IL-6 (pg/mg) Colon IL-8 (pg/mg) 200 4 20 150 3 15 Selective Wnt activation 2 100 10 **** **** ** ** *** 50 1 5 Epithelial **** **** **** **** **** **** **** **** **** repair
Slide 25: SZN-1326 – Reduces Disease Activity
SZN-1326 – Reduces Disease Activity Disease Activity Index (DAI) at Body Weight Percent Change Fecal Score Day 10 (BW, fecal score) at Day 10 at Day 10 Selective Wnt activation Epithelial repair SZN-1326 SZN-1326 SZN-1326 Inflammation SZN-1326 decreases disease activity scores in acute and reduction
Slide 26: SZN-1326 – Repairs Colon Epithelium In Vivo More Than Cyclosporine
SZN-1326 – Repairs Colon Epithelium In Vivo More Than Cyclosporine Cross Section of Transverse Colon: H&E Staining No DSS Anti-GFP Selective Wnt activation Epithelial repair Cyclosporine A SZN-1326 1 mpk BIW Inflammation reduction Functional improvement Surrozen in vivo study (SRZ-363): Administered
Slide 27: SZN-1326 – Improves Colon Histology Score More Than Cyclosporine
SZN-1326 – Improves Colon Histology Score In Vivo More Than Cyclosporine Selective Wnt activation Epithelial repair Inflammation reduction Functional improvement Statistical Analyses: One-way ANOVA, Holm-Sidak test (GraphPad Prism). All comparisons made with the anti-GFP group. Error bars: Mean with
Slide 28: SZN-1326 – Improves Disease Activity More Than Cyclosporine
SZN-1326 – Improves Disease Activity In Vivo More Than Cyclosporine Selective Wnt activation Epithelial repair Inflammation reduction Functional improvement Statistical Analyses: One-way ANOVA, Holm-Sidak test (GraphPad Prism). All comparisons made with the anti-GFP group. Error bars: Mean with SD.
Slide 29: SZN-1326 – Repairs Colon Epithelium Better Than Anti-TNF in Chronic Model
SZN-1326 – Repairs Colon Epithelium Better Than Anti-TNF in Chronic In Vivo Model No DSS Anti-GFP Selective Wnt activation Epithelial repair SZN-1326 1 mpk x4 Anti-TNF 25mpk x 7 Inflammation reduction Functional improvement Surrozen in vivo study (SRZ-0371): Administered 3% DSS in mice for three 7-d
Slide 30: SZN-1326 – Improves Colon Histology Score More Than Anti-TNF
SZN-1326 – Improves Colon Histology Score More Than Anti-TNF in Chronic In Vivo Model Selective Wnt activation Epithelial repair Inflammation reduction Functional improvement Statistical Analyses: One-way ANOVA, Holm-Sidak test (GraphPad Prism). All comparisons made with the anti-GFP group. Error ba
Slide 31: SZN-1326 – Improves Disease Activity More Than Anti-TNF
SZN-1326 – Improves Disease Activity More Than Anti-TNF in Chronic In Vivo Model Selective Wnt activation Epithelial repair Inflammation reduction Functional improvement Statistical Analyses: One-way ANOVA, Holm-Sidak test (GraphPad Prism). All comparisons made with the anti-GFP group. Error bars: M
Slide 32: SZN-043 Preclinical Data
Mutated RSPO2 Anti-ASGR1 IgG SZN-043 Preclinical Data Effector-less hIgG1 32Mutated RSPO2 Anti-ASGR1 IgG SZN-043 Preclinical Data Effector-less hIgG1 32
Slide 33: SZN-043 Selectively Stimulates Hepatocyte Proliferation
SZN-043 Selectively Stimulates Hepatocyte Proliferation Hepatocyte Proliferation Results in Rapid Improvement in Liver Function Ki-67 HNF4α Overlay Liver Mki67 Selective Wnt 20 24 h 48 h 72 h Anti-GFP activation SZN-043 **** 15 *** 10 Hepatocyte 5 Proliferation 0 Functional Improvement • SZN-043 ind
Slide 34: SZN-043 Reduces Markers of Liver Injury and Inflammation
SZN-043 Reduces Markers of Liver Injury and Inflammation Activity in Alcohol Injury Model Support Clinical Development Path Selective Wnt AST:ALT ratio Ammonia Liver IL6 activation AST/ALT Ratio Plasma Ammonia Liver IL6 20 300 8 D0 D3 D7 D0 D3 D7 D0 D3 D7 Pair Fed EtOH 15 6 ** Anti-GFP 200 SZN-043 1
Slide 35: Additional Information
Additional Information © 2021 Surrozen, Inc.Additional Information © 2021 Surrozen, Inc.
Slide 36: Glossary
Glossary AH – Alcoholic hepatitis IND – Investigational new Drug ALT – Alanine Aminotransferase Lille – Model for end-stage liver disease score AMD – Age-related macular degeneration Lrp – Lipoprotein receptor-related protein ASGR1 – Asiaglycoprotein receptor 1 MELD – Model for end-stage liver disea